GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reiterated by stock analysts at UBS AG in a report issued on Thursday, Analyst RN reports. They currently have a GBX 1,650 ($27.12) price target on the stock. UBS AG’s price objective suggests a potential upside of 4.46% from the company’s current price.
GlaxoSmithKline (LON:GSK) opened at 1567.91 on Thursday. GlaxoSmithKline has a 52-week low of GBX 1430.00 and a 52-week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1602. and a 200-day moving average of GBX 1618.93. The company’s market cap is £75.526 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at BNP Paribas reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday. They now have a GBX 1,600 ($26.29) price target on the stock. Separately, analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline from GBX 1,700 ($27.94) to GBX 1,620 ($26.62) in a research note to investors on Thursday. They now have a “hold” rating on the stock. Finally, analysts at Societe Generale cut their price target on shares of GlaxoSmithKline from GBX 1,960 ($32.21) to GBX 1,950 ($32.05) in a research note to investors on Monday. They now have a “buy” rating on the stock. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 1,718.82 ($28.25).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.